Cibinitide ARA-290 16mg Kit (10 Vials) 160mg For Sale – Fast Global Shipping

---

Most neuroprotective peptides block pain signals. Cibinitide ARA-290 repairs the nerve damage causing them — and that difference is everything. It’s why researchers globally are ordering this kit right now. If your lab studies neuropathic pain, inflammatory signaling, or tissue repair pathways, ARA-290 is the most targeted innate repair receptor agonist available today. Period.

This isn’t a compound that appears once in obscure literature and vanishes. Cibinitide ARA-290 has Phase 2 clinical trial data showing structural nerve fiber regrowth, improved neuropathic symptom scores, and measurable metabolic improvements, across sarcoidosis, diabetic neuropathy, and kidney protection models. Real data. Reproducible outcomes. And with this 10-vial, 160mg kit you get enough reagent to run serious, multi-arm protocols without constantly restocking mid-study.

Get your Cibinitide ARA-290 for sale here — 16mg per vial, 10 vials per kit, ≥99% purity, COA included, 36-month shelf life, fast global shipping.

---

What Is Cibinitide ARA-290?

Cibinitide — also known as ARA290, ARA-290, cibinetide, or PH-BSP (CAS: 1208243-50-8) — is a synthetic 11-amino acid peptide built from the helix B surface domain of erythropoietin (EPO). EPO naturally does two things: produces red blood cells and protects tissue from damage. Cibinitide ARA-290 was engineered to do only the second job — no hematocrit increase, no cardiovascular strain from blood thickening, no erythropoietic noise in your data. Just clean, precise tissue-protective signaling through one specific receptor target.

That target is the innate repair receptor (IRR) — a heterodimeric receptor complex built from EPOR and CD131. It sits dormant on nerve cells, immune cells, and endothelial cells until tissue damage wakes it up. When ARA-290 binds it, three things happen immediately: pro-inflammatory cytokines like TNF-α get suppressed, apoptotic death signals shut down, and the local environment flips from injury mode into active repair. It also separately antagonizes the TRPV1 nociception channel in peripheral nerve fibers — a second parallel pain-signaling pathway working simultaneously. Two mechanisms. One compact peptide.

Phase 2 clinical trials in sarcoidosis patients documented what almost no other research peptide has achieved — actual structural corneal nerve fiber regrowth measured by in-vivo confocal microscopy. Not just symptom score improvement. Physical, documented repair of damaged nerve tissue. That’s the research value of Cibinitide ARA-290 for sale in this kit.

---

ARA-290 vs Full-Length EPO — Why This Peptide Wins for Research

You might wonder why not just use full EPO. Fair question. Here’s the problem — full EPO fires two receptor systems at once: the tissue-protective IRR and the erythropoietic EPOR homodimer that raises red blood cell count. That dual activation creates confounders in your data and introduces cardiovascular risk concerns that make it unsuitable for many research protocols. Cibinitide ARA-290 is selective. It hits the IRR only. Your data stays clean. Your mechanism stays interpretable. That selectivity is the entire point — and it’s why this peptide keeps appearing across neuropathy, autoimmune, metabolic, and nephroprotection research programs worldwide.

---

What Researchers Use ARA-290 For

Neuropathic Pain and Small Fiber Neuropathy This is where Cibinitide ARA-290 has its deepest, most documented research track record. Small fiber neuropathy affects 40–60% of sarcoidosis patients, and standard immunosuppressive therapy barely touches it. ARA-290 reduces inflammatory signals around damaged nerve fibers, blocks apoptosis in stressed neurons, and — uniquely — promotes nerve fiber regrowth. Phase 2 trials showed neuropathic symptom scores improving significantly versus placebo, alongside documented structural nerve fiber repair in the cornea. No other compound in this space has that combination on record.

Diabetic Neuropathy and Metabolic Research In Phase 2 trials involving type 2 diabetes patients with painful neuropathy, ARA-290 improved HbA1c levels, lipid profiles, and neuropathic symptom scores simultaneously — pointing to a compound that touches both metabolic control and nerve function in the same protocol. For labs studying the intersection of metabolic disease and neurological damage, that dual activity is difficult to replicate with any single alternative compound.

Inflammatory Disease Models Cibinitide dampens innate immune cell function and reduces pro-inflammatory cytokine activity across multiple cell types. Research in experimental colitis models showed it ameliorates inflammatory disease progression through IRR-mediated immune modulation — making it relevant for autoimmune and chronic inflammatory disease research well beyond neuropathy.

Kidney Protection A 2023 study in Inflammation confirmed ARA-290‘s protective effects against cisplatin-induced nephrotoxicity through anti-apoptosis and anti-inflammatory mechanisms — opening a meaningful nephroprotection research application for labs working in oncology support and renal biology.

Ocular Research A Phase 2 clinical trial evaluated Cibinitide for diabetic macular edema with results suggesting retinal tissue protection potential. Corneal nerve fiber density has also been used as a measurable biomarker of ARA-290 biological activity across multiple trials — making it a useful readout tool for ocular research protocols.

Bone Biology Research published in Int J Mol Sci (2021) showed Cibinetide inhibits osteoclastogenesis in vitro and increases bone mineral density in mice — an emerging application for osteoporosis and bone remodeling research programs.

---

Kit Specifications

Note on vial cap color: In cases where assigned top colors are out of stock, a different color cap will be used to ensure your order ships without delay. Contents and specifications remain identical.

---

How to Use Cibinitide ARA-290 — Reconstitution Guide

What You Need

How to Reconstitute — Step by Step

Step 1 — Let It Warm Up Take your ARA-290 vial out of cold storage 10–15 minutes before starting. Let it reach room temperature naturally before opening. Cold-to-cold reconstitution affects how evenly the powder dissolves.

Step 2 — Disinfect the Stopper Wipe the rubber stopper with a 70% IPA swab. Wait 30 seconds for it to dry fully. Do this every single time — including when you come back for subsequent doses from the same vial. Contamination is invisible and ruins protocols quietly.

Step 3 — Inject BAC Water Along the Vial Wall Draw your target BAC water volume into the sterile syringe. Insert the needle and angle it so the water runs slowly down the inner glass wall — not directly onto the powder. This protects the peptide from foaming and mechanical stress. Take your time. Rushing this step costs you reagent.

Step 4 — Swirl Gently. Never Shake. Roll the vial slowly between your palms in a circular motion for 2–3 minutes. The product specification is explicit on this — do not shake before or after reconstitution. Shaking damages the peptide structure and compromises your results. Swirl until you get a clear, uniform solution with no visible particles.

Step 5 — Inspect the Solution Clear to very slightly pale yellow — good to go. Cloudy, discolored, or particulate — discard immediately. A compromised vial from a 10-vial kit is frustrating and expensive. Inspect every single time before use.

Step 6 — Label and Refrigerate Write the reconstitution date, concentration, and your initials on the vial right now — not later. Refrigerate immediately at 2–8°C. Use within 28 days. Keep it away from direct light between uses.

---

How to Store Cibinitide ARA-290

One important habit — never shake the vial after reconstitution either. Refrigerate it upright. And if you’re returning to a multi-dose vial, always re-swab the stopper before drawing. These small things protect a 36-month-shelf-life investment from becoming a 3-week mistake.

---

Why Buy This Kit and Not Individual Vials?

Simple math. You get 160mg of research-grade Cibinitide ARA-290 in one order — enough for complete, multi-arm experimental designs without mid-study supply interruptions. Serious metabolic, neuropathy, and inflammatory signaling research needs protocol consistency. Switching batches mid-study introduces variables. Getting your full supply in one verified, COA-documented kit removes that problem entirely.

Plus, ARA-290’s 36-month shelf life means there’s no pressure to race through your reagent. Stock your lab correctly once, run your protocols properly, and trust your data. That’s the value of the 10-vial kit structure — and why researchers globally order it this way.

---

FAQs About Cibinitide ARA-290 for sale

1. What are the medical uses of Cibinitide ARA-290?

ARA-290 is studied in neuropathic pain, small fiber neuropathy, sarcoidosis, diabetic neuropathy, inflammatory disease, kidney protection, and ocular research models. It’s not FDA-approved for clinical use — it’s available for qualified laboratory research only. The strongest human data comes from neuropathic pain and nerve fiber regeneration studies.

---

2. What is Cibinitide and what is it primarily used for in research?

Cibinitide is a synthetic EPO-derived peptide that selectively activates the innate repair receptor to reduce inflammation, block cell death, and promote tissue repair — without affecting red blood cell production. Labs use it primarily for neuropathic pain signaling, anti-inflammatory pathway research, metabolic disease models, and nerve fiber regeneration studies.

---

3. Where can I buy Cibinitide ARA-290 in the US and globally?

Cibinitide ARA-290 for sale is available at swisschemsofficial.com as a 10-vial, 160mg kit with ≥99% purity, COA included, and fast global shipping. Qualified researchers in the USA, Canada, Germany, France, Australia, and worldwide can order directly online.

---

4. How does ARA-290 interact with the immune system?

It activates the innate repair receptor on immune cells including monocytes and macrophages, triggering JAK2-mediated suppression of pro-inflammatory cytokines like TNF-α. The immune environment shifts from inflammatory attack mode toward pro-resolution healing — which is why it shows activity across both neuropathy and autoimmune disease research models.

---

5. Are there any approved drugs containing ARA-290?

No. Cibinitide ARA-290 is investigational — it has completed Phase 2 trials but holds no FDA, EMA, or Health Canada approval for clinical use. It is available for qualified laboratory research only, not for prescription or therapeutic administration.

---

6. What are the side effects of Cibinitide ARA-290?

Across all published human trials, ARA-290 raised no serious safety concerns. Mild adverse events included occasional injection site reactions, transient headache, or mild GI discomfort. No erythropoietic effects, no hematocrit changes, no cardiovascular signals. Its safety profile across Phase 1 and Phase 2 trials is consistently described as excellent in published literature.

---

7. Is Cibinitide available by prescription in the US?

No. Cibinitide ARA-290 is not available by prescription anywhere. It is sold for sale to qualified researchers for in vitro laboratory use only — not for clinical administration, personal use, or veterinary applications.

---

8. Which companies manufacture ARA-290 peptide?

Cibinitide ARA-290 was originally developed by Araim Pharmaceuticals. Research-grade material is available through verified peptide suppliers globally. When purchasing, always confirm ≥99% HPLC purity documentation and a third-party COA — quality varies significantly between suppliers and directly impacts your data reliability.

---

9. How does ARA-290 compare to semaglutide or other research peptides for metabolic research?

Different mechanism entirely. Semaglutide targets GLP-1 receptors for glycemic control and weight management. Cibinitide ARA-290 targets the innate repair receptor for tissue protection, anti-inflammation, and nerve repair. In diabetic research models, ARA-290 improved HbA1c and lipid profiles alongside neuropathic symptom scores — making it relevant for researchers studying the metabolic-neurological intersection rather than pure glycemic control.

---

10. Does ARA-290 increase red blood cell count?

No — and this is by deliberate design. Cibinitide ARA-290 binds the EPOR/CD131 heterodimer exclusively — not the EPOR homodimer responsible for erythropoiesis. Red blood cell production stays completely unaffected. That selectivity is its core pharmacological advantage over full-length EPO and the reason it produces cleaner data in tissue-protective research protocols.

---

11. How long does reconstituted ARA-290 stay stable?

Once reconstituted with bacteriostatic water, Cibinitide ARA-290 remains stable refrigerated at 2–8°C for up to 28 days. Keep it away from light between uses, never freeze the reconstituted solution, and always inspect for clarity before each use. The lyophilized powder in sealed vials lasts 36 months at proper storage temperatures.

---

12. Can ARA-290 be stacked or combined with other research peptides?

In research protocols, ARA-290 is sometimes studied alongside metabolic compounds like NMN or NAD+ precursors for complementary cellular repair coverage — one working on inflammation and nerve repair, the other on energy metabolism. Always design combination protocols with appropriate controls to isolate each compound’s contribution to your data.

---

⚠️ Research Use Only: Cibinitide ARA-290 is intended strictly for in vitro laboratory research by qualified professionals. Not for human or animal consumption. Not evaluated or approved by the FDA, EMA, or Health Canada. Buyers confirm compliance with all applicable local regulations.